Logo image of GTBP

GT BIOPHARMA INC (GTBP) Stock Fundamental Analysis

NASDAQ:GTBP - Nasdaq - US36254L3087 - Common Stock - Currency: USD

2.44  +0.07 (+2.95%)

Fundamental Rating

2

GTBP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. GTBP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GTBP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GTBP had negative earnings in the past year.
In the past year GTBP has reported a negative cash flow from operations.
GTBP had negative earnings in each of the past 5 years.
In the past 5 years GTBP always reported negative operating cash flow.
GTBP Yearly Net Income VS EBIT VS OCF VS FCFGTBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

GTBP has a Return On Assets of -182.70%. This is amonst the worse of the industry: GTBP underperforms 87.61% of its industry peers.
The Return On Equity of GTBP (-588.89%) is worse than 80.63% of its industry peers.
Industry RankSector Rank
ROA -182.7%
ROE -588.89%
ROIC N/A
ROA(3y)-163.21%
ROA(5y)-233.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GTBP Yearly ROA, ROE, ROICGTBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20K -20K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GTBP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GTBP Yearly Profit, Operating, Gross MarginsGTBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for GTBP has been increased compared to 1 year ago.
The number of shares outstanding for GTBP has been increased compared to 5 years ago.
GTBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GTBP Yearly Shares OutstandingGTBP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
GTBP Yearly Total Debt VS Total AssetsGTBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -148.87, we must say that GTBP is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GTBP (-148.87) is worse than 96.86% of its industry peers.
There is no outstanding debt for GTBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -148.87
ROIC/WACCN/A
WACCN/A
GTBP Yearly LT Debt VS Equity VS FCFGTBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 1.45 indicates that GTBP should not have too much problems paying its short term obligations.
The Current ratio of GTBP (1.45) is worse than 81.85% of its industry peers.
A Quick Ratio of 1.45 indicates that GTBP should not have too much problems paying its short term obligations.
GTBP has a Quick ratio of 1.45. This is amonst the worse of the industry: GTBP underperforms 80.98% of its industry peers.
Industry RankSector Rank
Current Ratio 1.45
Quick Ratio 1.45
GTBP Yearly Current Assets VS Current LiabilitesGTBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

GTBP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.19%, which is quite impressive.
EPS 1Y (TTM)71.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

GTBP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.60% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.62%
EPS Next 2Y27.6%
EPS Next 3Y19.48%
EPS Next 5Y12.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GTBP Yearly Revenue VS EstimatesGTBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20B 40B 60B 80B
GTBP Yearly EPS VS EstimatesGTBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GTBP. In the last year negative earnings were reported.
Also next year GTBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GTBP Price Earnings VS Forward Price EarningsGTBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GTBP Per share dataGTBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as GTBP's earnings are expected to grow with 19.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.6%
EPS Next 3Y19.48%

More info and screens

0

5. Dividend

5.1 Amount

GTBP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GT BIOPHARMA INC

NASDAQ:GTBP (3/7/2025, 8:00:01 PM)

2.44

+0.07 (+2.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-21 2025-02-21/amc
Earnings (Next)05-13 2025-05-13
Inst Owners64.1%
Inst Owner Change-0.26%
Ins Owners3.3%
Ins Owner Change0%
Market Cap5.44M
Analysts82.86
Price Target11.22 (359.84%)
Short Float %9.6%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)48.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-197.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.59
P/tB 2.59
EV/EBITDA N/A
EPS(TTM)-5.79
EYN/A
EPS(NY)-2.15
Fwd EYN/A
FCF(TTM)-5.6
FCFYN/A
OCF(TTM)-5.6
OCFYN/A
SpS0
BVpS0.94
TBVpS0.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -182.7%
ROE -588.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-163.21%
ROA(5y)-233.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.45
Quick Ratio 1.45
Altman-Z -148.87
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.2%
EPS Next Y-19.62%
EPS Next 2Y27.6%
EPS Next 3Y19.48%
EPS Next 5Y12.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-98952%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.43%
OCF growth 3YN/A
OCF growth 5YN/A